Vaccines Market to 2027- Global Analysis and Forecasts by Technology (Recombinant Vaccines, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated and Subunit Vaccines, and Toxoid Vaccines); Disease Indication (DTP (Diphtheria Tetanus toxoids and Pertussis), Influenza, Hepatitis, Respiratory Syncytial Virus (RSV), and Other Diseases); Route of Administration (Oral, Injectable, and Other Routes of Administration); Patient Type (Pediatric Patients, and Adult Patients) and Geography
- THE3206979
- 184 Pages
- March 2019
- Pharmaceuticals
The major driving factors are rising prevalence of infectious diseases, growing focus on immunization programs, and increasing support for vaccine development are expected to boost the market growth over the years. However, soaring prices of the vaccines and complexity and cost of vaccine manufacturing are likely to pose a negative impact on the market growth. On the other hand, robust pipeline of vaccines is likely to have a positive impact on the growth of the global vaccines market in the coming years. In the current era, there are increasing concerns of spread of infectious diseases with the changing environment. These emerging infectious diseases are a burden on public health but have also an impact on global economies. The new diseases such as HIV, hepatitis, dengue have attracted a huge concern for the government of the respective countries. There is also resurgence of diseases which seemed to be under control such as malaria, cholera and many more. According to the Centers for Disease control and Prevention in 2015, 16.8 million people in the US visited hospitals due to infectious and parasitic diseases. In Africa, chronic viral hepatitis affects around 70 million Africans (60 million with Hepatitis B and 10 million with Hepatitis C). The disease impacts the most important part of the African population i.e. youths and earning African population which are causing tremendous rise in financial debts incurred for the treatment of advanced liver diseases and emotional distress. Thus the growing global prevalence of infectious diseases are expected to encourage the leading market players for the development of new and effective drugs and vaccines.
The vaccines market by technology is segmented into Recombinant vaccines, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, and Toxoid Vaccines. In 2018, the conjugate vaccines segment held a largest market share of 65.1% of the vaccines market, By Technology. This segment is also expected to dominate the market in 2027 as they are the most effective forms of immunization, used to prevent diseases in both infants and adults. Moreover, the similar segment is anticipated to also witness the fastest growth rate of 6.7% during the forecast period, 2019 to 2027 owing to the increasing demand for drugs to treat the disease.
The global vaccines market on the patient type is segmented into pediatric patients and adult patients. In 2018, the pediatric segment held a largest market share of 70.0% of the vaccines market, by patient type. This segment is also expected to dominate the market in 2027 as external immunization is necessary for the new borns. Moreover, vaccines have helped the children in staying healthy and been successful to save millions of lives for more than 50 years.
Some of the major primary and secondary sources for vaccines included in the report are World Health Organization (WHO), European Medical Agency (EMA), Advisory Committee on Immunization Practices (ACIP), China Food and Drug Administration (CFDA), Council of Scientific and Industrial Research (CSIR), French Scientific Research Centre (FSRC), and others.
1. INTRODUCTION
1.1 SCOPE OF THE STUDY
1.2 THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3 MARKET SEGMENTATION
1.3.1 Global Vaccines Market - By Technology
1.3.2 Global Vaccines Market - By Disease Indication
1.3.3 Global Vaccines Market - By Route of Administration
1.3.4 Global Vaccines Market - By Patient Type
1.3.5 Global Vaccines Market - By Geography
2. GLOBAL VACCINES MARKET - KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 COVERAGE
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
4. GLOBAL VACCINES MARKET - MARKET LANDSCAPE
4.1 OVERVIEW
4.2 PEST ANALYSIS
4.2.1 North America - PEST Analysis
4.2.2 Europe- PEST Analysis
4.2.3 Asia Pacific- PEST Analysis
4.2.4 Middle East & Africa- PEST Analysis
4.2.5 South and Central America - PEST Analysis
5. GLOBAL VACCINES MARKET - KEY MARKET DYNAMICS
5.1 KEY MARKET DRIVERS
5.1.1 Rising Prevalence of Infectious Diseases
5.1.2 Growing Focus on Immunization Programs
5.1.3 Increasing Support for Vaccine Development
5.2 KEY MARKET RESTRAINTS
5.2.1 The Complexity And Cost of Vaccine Manufacturing
5.2.2 Soaring Costs of Vaccines
5.3 KEY MARKET OPPORTUNITIES
5.3.1 Robust Pipeline of Vaccines
5.4 FUTURE TRENDS
5.4.1 New Vaccine Delivery Systems
5.5 IMPACT ANALYSIS
6. VACCINES MARKET - GLOBAL ANALYSIS
6.1 GLOBAL VACCINES MARKET REVENUE FORECASTS AND ANALYSIS
6.2 GLOBAL VACCINES MARKET, BY GEOGRAPHY - FORECASTS AND ANALYSIS
6.3 PERFORMANCE OF KEY PLAYERS
6.3.1 GlaxoSmithKline plc
6.3.2 Sanofi
7. VACCINES MARKET ANALYSIS AND FORECASTS TO 2027 - TECHNOLOGY
7.1 OVERVIEW
7.2 TECHNOLOGY MARKET REVENUE AND FORECASTS ANALYSIS (US$ MN)
7.3 RECOMBINANT VACCINES MARKET
7.3.1 Overview
7.3.2 Recombinant Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
7.4 CONJUGATE VACCINES MARKET
7.4.1 Overview
7.4.2 Conjugate Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
7.5 LIVE ATTENUATED VACCINES MARKET
7.5.1 Overview
7.5.2 Live Attenuated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
7.6 INACTIVATED VACCINES MARKET
7.6.1 Overview
7.6.2 Inactivated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
7.7 TOXOID VACCINES MARKET
7.7.1 Overview
7.7.2 Toxoid Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
8. VACCINES MARKET ANALYSIS AND FORECASTS TO 2027 - DISEASE INDICATION
8.1 OVERVIEW
8.2 DISEASE INDICATION MARKET REVENUE AND FORECASTS ANALYSIS (US$ MN)
8.3 DTP (DIPHTHERIA, TETANUS, AND PERTUSSIS) MARKET
8.3.1 Overview
8.3.2 DTP (Diphtheria, Tetanus, And Pertussis) Market Revenue and Forecast to 2027 (US$ Mn)
8.4 INFLUENZA MARKET
8.4.1 Overview
8.4.2 Influenza Market Revenue and Forecast to 2027 (US$ Mn)
8.5 HEPATITIS MARKET
8.5.1 Overview
8.5.2 Hepatitis Market Revenue and Forecast to 2027 (US$ Mn)
8.6 RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET
8.6.1 Overview
8.6.2 Respiratory Syncytial Virus (RSV) Market Revenue and Forecast to 2027
(US$ Mn)
8.7 OTHER DISEASES MARKET
8.7.1 Overview
8.7.2 Other Diseases Market Revenue and Forecast to 2027 (US$ Mn)
9. VACCINES MARKET ANALYSIS AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ROUTE OF ADMINISTRATION MARKET REVENUE AND FORECASTS ANALYSIS
(US$ MN)
9.3 ORAL MARKET
9.3.1 Overview
9.3.2 Oral Market Revenue and Forecast to 2027 (US$ Mn)
9.4 INJECTABLE MARKET
9.4.1 Overview
9.4.2 Injectable Market Revenue and Forecast to 2027 (US$ Mn)
9.5 OTHER ROUTES OF ADMINISTRATION MARKET
9.5.1 Overview
9.5.2 Other Routes of Administration Market Revenue and Forecast to 2027
(US$ Mn)
10. VACCINES MARKET ANALYSIS AND FORECASTS TO 2027 - PATIENT TYPE
10.1 OVERVIEW
10.2 PATIENT TYPE MARKET REVENUE AND FORECASTS ANALYSIS (US$ MN)
10.3 PEDIATRIC MARKET
10.3.1 Overview
10.3.2 Pediatric Market Revenue and Forecast to 2027 (US$ Mn)
10.4 ADULTS MARKET
10.4.1 Overview
10.4.2 Adults Market Revenue and Forecast to 2027 (US$ Mn)
11. VACCINES MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
11.1 NORTH AMERICA VACCINES MARKET
11.1.1 Overview
11.1.2 North America Vaccines Market Revenue And Forecasts to 2027 (US$ Mn)
11.1.3 North America Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.1.4 North America Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.1.5 North America Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.1.6 North America Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.1.7 North America Vaccines Market Revenue And Forecasts to 2027, By Country (%)
11.1.8 US Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.9 US Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.9.1 US Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.1.9.2 US Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.1.9.3 US Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.1.9.4 US Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.1.10 Canada Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.11 Canada Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.11.1 Canada Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.1.11.2 Canada Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.1.11.3 Canada Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.1.11.4 Canada Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.1.12 Mexico Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.13 Mexico Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.13.1 Mexico Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.1.13.2 Mexico Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.1.13.3 Mexico Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.1.13.4 Mexico Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.2 EUROPE VACCINES MARKET
11.2.1 Overview
11.2.2 Europe Vaccines Market Revenue Overview, by Country (2017) (US$ Mn)
11.2.3 Europe Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.4 Europe Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.2.5 Europe Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.2.6 Europe Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.2.7 Europe Vaccines Market Revenue And Forecasts to 2027, By Patient Type
(US$ Mn)
11.2.8 Europe Vaccines Market Revenue and Forecasts to 2027, By Country (%)
11.2.9 Germany Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.10 Germany Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.10.1 Germany Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.2.10.2 Germany Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.2.10.3 Germany Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.2.10.4 Germany Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.2.11 UK Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.12 UK Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.12.1 UK Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.2.12.2 UK Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.2.12.3 UK Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.2.12.4 UK Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.2.13 France Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.14 France Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.14.1 France Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.2.14.2 France Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.2.14.3 France Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.2.14.4 France Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.2.15 Italy Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.16 Italy Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.16.1 Italy Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.2.16.2 Italy Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.2.16.3 Italy Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.2.16.4 Italy Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.2.17 Spain Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.18 Spain Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.18.1 Spain Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.2.18.2 Spain Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.2.18.3 Spain Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.2.18.4 Spain Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.3 ASIA PACIFIC VACCINES MARKET
11.3.1 Overview
11.3.2 Asia Pacific Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.3 Asia Pacific Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.3.4 Asia Pacific Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.3.5 Asia Pacific Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.3.6 Asia Pacific Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.3.7 Asia Pacific Vaccines Market Revenue and Forecasts to 2027, By Country (%)
11.3.8 China Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.9 China Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.9.1 China Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.3.9.2 China Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.3.9.3 China Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.3.9.4 China Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.3.10 Japan Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.11 Japan Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.11.1 Japan Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.3.11.2 Japan Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.3.11.3 Japan Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.3.11.4 Japan Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.3.12 India Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.13 India Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.13.1 India Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.3.13.2 India Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.3.13.3 India Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.3.13.4 India Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.3.14 Australia Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.15 Australia Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.15.1 Australia Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.3.15.2 Australia Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.3.15.3 Australia Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.3.15.4 Australia Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.3.16 South Korea Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.17 South Korea Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.17.1 South Korea Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.3.17.2 South Korea Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.3.17.3 South Korea Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.3.17.4 South Korea Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.4 MIDDLE EAST & AFRICA VACCINES MARKET
11.4.1 Middle East & Africa Vaccines Market Revenue and Forecasts to 2027
(US$ Mn)
11.4.2 Middle East & Africa Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.4.3 Middle East & Africa Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.4.4 Middle East & Africa Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.4.5 Middle East & Africa Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.4.6 Middle East & Africa Vaccines market Revenue and Forecasts to 2027, By Country (%)
11.4.7 UAE Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.8 UAE Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.8.1 UAE Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.4.8.2 UAE Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.4.8.3 UAE Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.4.8.4 UAE Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.4.9 Saudi Arabia Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.10 Saudi Arabia Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.10.1 Saudi Arabia Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.4.10.2 Saudi Arabia Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.4.10.3 Saudi Arabia Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.4.10.4 Saudi Arabia Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.4.11 South Africa Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.12 South Africa Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.12.1 South Africa Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.4.12.2 South Africa Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.4.12.3 South Africa Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.4.12.4 South Africa Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.5 SOUTH AND CENTRAL AMERICA VACCINES MARKET
11.5.1 Overview
11.5.2 South and Central America Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.5.3 South and Central America Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.5.4 South and Central America Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.5.5 South and Central America Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.5.6 South and Central America Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.5.7 South and Central America Vaccines Market Share by Country, 2017 and 2027 (%)
11.5.8 Brazil Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.5.9 Brazil Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.5.9.1 Brazil Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.5.9.2 Brazil Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.5.9.3 Brazil Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.5.9.4 Brazil Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11.5.10 Argentina Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.5.11 Argentina Vaccines market Revenue and Forecasts to 2027 (US$ Mn)
11.5.11.1 Argentina Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
11.5.11.2 Argentina Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
11.5.11.3 Argentina Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
11.5.11.4 Argentina Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
12. VACCINES MARKET - INDUSTRY LANDSCAPE
12.1 OVERVIEW
12.2 COMPARATIVE COMPANY ANALYSIS
12.3 GROWTH STRATEGIES DONE BY THE COMPANIES IN THE MARKET, (%)
12.4 ORGANIC DEVELOPMENTS
12.4.1 Overview
12.5 INORGANIC DEVELOPMENTS
12.5.1 Overview
13. VACCINES MARKET -KEY COMPANY PROFILES
13.1 PFIZER INC.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Financial Overview
13.1.4 Product Portfolio
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 GLAXOSMITHKLINE PLC.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Financial Overview
13.2.4 Product Portfolio
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 MERCK & CO., INC.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Financial Overview
13.3.4 Product Portfolio
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 SANOFI
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Financial Information
13.4.4 Product Portfolio
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 JOHNSON & JOHNSON SERVICES, INC.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Financial Overview
13.5.4 Product Portfolio
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 PANACEA BIOTEC LIMITED
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Financial Information
13.6.4 Product Portfolio
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 ASTELLAS PHARMA INC.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Financial Overview
13.7.4 Product Portfolio
13.7.5 Swot Analysis
13.7.6 Key Developments
13.8 NOVAVAX, INC.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Financial Information
13.8.4 Product Pipeline
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 VBI VACCINES INC.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Financial Information
13.9.4 Product Portfolio
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 BAVARIAN NORDIC
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Financial Information
13.10.4 Product Pipeline
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 ABOUT THE INSIGHT PARTNERS
14.2 GLOSSARY OF TERMS
LIST OF TABLES
TABLE 1. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY TECHNOLOGY (US$ MN)
TABLE 2. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY DISEASE INDICATION (US$ MN)
TABLE 3. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 4. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY PATIENT TYPE (US$ MN)
TABLE 5. US VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 6. US VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 7. US VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 8. US VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 9. CANADA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY TECHNOLOGY (US$ MN)
TABLE 10. CANADA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 11. CANADA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 12. CANADA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 13. MEXICO VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY TECHNOLOGY (US$ MN)
TABLE 14. MEXICO VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 15. MEXICO VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 16. MEXICO VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 17. EUROPE VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY TECHNOLOGY (US$ MN)
TABLE 18. EUROPE VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 19. EUROPE VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 20. EUROPE VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 21. GERMANY VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY TECHNOLOGY (US$ MN)
TABLE 22. GERMANY VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 23. GERMANY VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 24. GERMANY VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 25. UK VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 26. UK VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 27. UK VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 28. UK VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 29. FRANCE VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY TECHNOLOGY (US$ MN)
TABLE 30. FRANCE VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 31. FRANCE VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 32. FRANCE VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 33. ITALY VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 34. ITALY VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 35. ITALY VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 36. ITALY VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 37. SPAIN VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 38. SPAIN VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 39. SPAIN VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 40. SPAIN VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 41. ASIA PACIFIC VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY TECHNOLOGY (US$ MN)
TABLE 42. ASIA PACIFIC VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY DISEASE INDICATION (US$ MN)
TABLE 43. ASIA PACIFIC VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 44. ASIA PACIFIC VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 45. CHINA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 46. CHINA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 47. CHINA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 48. CHINA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 49. JAPAN VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 50. JAPAN VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 51. JAPAN VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 52. JAPAN VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 53. INDIA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 54. INDIA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 55. INDIA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 56. INDIA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 57. AUSTRALIA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY TECHNOLOGY (US$ MN)
TABLE 58. AUSTRALIA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 59. AUSTRALIA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 60. AUSTRALIA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 61. SOUTH KOREA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY TECHNOLOGY (US$ MN)
TABLE 62. SOUTH KOREA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY DISEASE INDICATION (US$ MN)
TABLE 63. SOUTH KOREA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 64. SOUTH KOREA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY PATIENT TYPE (US$ MN)
TABLE 65. MIDDLE EAST & AFRICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 66. MIDDLE EAST & AFRICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 67. MIDDLE EAST & AFRICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 68. MIDDLE EAST & AFRICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 69. UAE VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 70. UAE VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 71. UAE VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 72. UAE VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 73. SAUDI ARABIA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY TECHNOLOGY (US$ MN)
TABLE 74. SAUDI ARABIA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY DISEASE INDICATION (US$ MN)
TABLE 75. SAUDI ARABIA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 76. SAUDI ARABIA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY PATIENT TYPE (US$ MN)
TABLE 77. SOUTH AFRICA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY TECHNOLOGY (US$ MN)
TABLE 78. SOUTH AFRICA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY DISEASE INDICATION (US$ MN)
TABLE 79. SOUTH AFRICA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 80. SOUTH AFRICA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY PATIENT TYPE (US$ MN)
TABLE 81. SOUTH AND CENTRAL AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 82. SOUTH AND CENTRAL AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 83. SOUTH AND CENTRAL AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 84. SOUTH AND CENTRAL AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 85. BRAZIL VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
TABLE 86. BRAZIL VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 87. BRAZIL VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 88. BRAZIL VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 89. ARGENTINA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY TECHNOLOGY (US$ MN)
TABLE 90. ARGENTINA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
TABLE 91. ARGENTINA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
TABLE 92. ARGENTINA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
TABLE 93. ORGANIC DEVELOPMENTS DONE BY COMPANIES
TABLE 94. INORGANIC DEVELOPMENTS DONE BY COMPANIES
TABLE 95. GLOSSARY OF TERMS, VACCINES MARKET
LIST OF FIGURES
FIGURE 1. VACCINES MARKET SEGMENTATION
FIGURE 2. VACCINES SEGMENTATION, BY REGION
FIGURE 3. ASIA PACIFIC VACCINES MARKET, REVENUE (US$ MN), BY GEOGRAPHY
2018 & 2027
FIGURE 4. GLOBAL VACCINES MARKET BY TECHNOLOGY, MARKET SHARE (%), 2018
FIGURE 5. GLOBAL VACCINES MARKET BY DISEASE INDICATION, MARKET SHARE (%), 2018
FIGURE 6. GLOBAL VACCINES MARKET BY ROUTE OF ADMINISTRATION, MARKET SHARE (%), 2018
FIGURE 7. GLOBAL VACCINES MARKET BY PATIENT TYPE, MARKET SHARE (%), 2018
FIGURE 8. NORTH AMERICA PEST ANALYSIS
FIGURE 9. EUROPE PEST ANALYSIS
FIGURE 10. ASIA PACIFIC PEST ANALYSIS
FIGURE 11. MIDDLE EAST & AFRICA PEST ANALYSIS
FIGURE 12. SOUTH AND CENTRAL AMERICA PEST ANALYSIS
FIGURE 13. VACCINES MARKET IMPACT ANALYSIS OF DRIVER AND RESTRAINTS
FIGURE 14. GLOBAL VACCINES MARKET - REVENUE FORECASTS AND ANALYSIS -2018- 2027
FIGURE 15. GLOBAL VACCINES MARKET - BY GEOGRAPHY FORECASTS AND ANALYSIS - 2018- 2027
FIGURE 16. TECHNOLOGY MARKET ANALYSIS AND FORECASTS 2018 AND 2027 (%)
FIGURE 17. RECOMBINANT VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 18. CONJUGATE VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 19. LIVE ATTENUATED VACCINES MARKET REVENUE AND FORECASTS TO 2027
(US$ MN)
FIGURE 20. INACTIVATED VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 21. TOXOID VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 22. DISEASE INDICATION MARKET ANALYSIS AND FORECASTS 2018 AND 2027 (%)
FIGURE 23. DTP (DIPHTHERIA, TETANUS, AND PERTUSSIS) MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 24. INFLUENZA MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 25. HEPATITIS MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 26. RESPIRATORY SYNCYTIAL VIRUS (RSV) MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 27. OTHER DISEASES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 28. ROUTE OF ADMINISTRATION MARKET ANALYSIS AND FORECASTS 2018 AND 2027 (%)
FIGURE 29. ORAL MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 30. INJECTABLE MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 31. OTHER ROUTES OF ADMINISTRATION MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 32. PATIENT TYPE MARKET ANALYSIS AND FORECASTS 2018 AND 2027 (%)
FIGURE 33. PEDIATRIC MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 34. ADULTS MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 35. NORTH AMERICA VACCINES MARKET REVENUE OVERVIEW, BY COUNTRY (2017) (US $ MN)
FIGURE 36. NORTH AMERICA MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 37. NORTH AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY COUNTRY (%)
FIGURE 38. US VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 39. CANADA VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 40. MEXICO VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 41. EUROPE VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 42. EUROPE VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY COUNTRY (%)
FIGURE 43. GERMANY VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 44. UK VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 45. FRANCE VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 46. ITALY VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 47. SPAIN VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 48. ASIA PACIFIC VACCINES MARKET REVENUE OVERVIEW, BY COUNTRY (2018)
(US $ MN)
FIGURE 49. ASIA PACIFIC MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 50. ASIA PACIFIC VACCINES MARKET REVENUE AND FORECASTS TO 2027,
BY COUNTRY (%)
FIGURE 51. CHINA VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 52. JAPAN VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 53. INDIA VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 54. AUSTRALIA VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 55. SOUTH KOREA VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 56. MIDDLE EAST & AFRICA VACCINES MARKET REVENUE, BY COUNTRY, 2018
(US$ MN)
FIGURE 57. MIDDLE EAST & AFRICA VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 58. MIDDLE EAST & AFRICA VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY COUNTRY (%)
FIGURE 59. UAE VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 60. SAUDI ARABIA VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 61. SOUTH AFRICA VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 62. SOUTH AND CENTRAL AMERICA VACCINES MARKET REVENUE, BY COUNTRY,
2017 (US$ MN)
FIGURE 63. SOUTH AND CENTRAL AMERICA VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 64. SOUTH AND CENTRAL AMERICA VACCINES MARKET SHARE BY COUNTRY,
2017 AND 2027 (%)
FIGURE 65. BRAZIL VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 66. ARGENTINA VACCINES MARKET REVENUE AND FORECASTS TO 2027 (US$ MN)
FIGURE 67. COMPARATIVE COMPANY ANALYSIS
FIGURE 68. GROWTH STRATEGIES DONE BY THE COMPANIES IN THE MARKET, (%)
Similar Reports
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
- Publish Date: November 14, 2017
- $5370
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
- Publish Date: July 20, 2017
- $5370
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...
- Publish Date: April 24, 2017
- $5370
